159 related articles for article (PubMed ID: 15973557)
1. Digestive Disease Week 2005. Drug highlights I.
De La Rue SA
IDrugs; 2005 Jul; 8(7):537-8. PubMed ID: 15973557
[No Abstract] [Full Text] [Related]
2. Digestive Disease Week 2005. Drug highlights II.
De La Rue SA
IDrugs; 2005 Jul; 8(7):539-41. PubMed ID: 15973558
[No Abstract] [Full Text] [Related]
3. Digestive Disease Week 2009. Turning science into medicine: Part 2.
Glah DR
IDrugs; 2009 Aug; 12(8):471-3. PubMed ID: 19629876
[No Abstract] [Full Text] [Related]
4. Digestive Disease Week 2007. Updates from established drugs.
Chan D
IDrugs; 2007 Jul; 10(7):436-8. PubMed ID: 17642008
[No Abstract] [Full Text] [Related]
5. American Society of Clinical Oncology--41st annual meeting. Drug highlights II.
Shah S; Yager N
IDrugs; 2005 Jul; 8(7):534-6. PubMed ID: 15973556
[No Abstract] [Full Text] [Related]
6. Digestive Disease Week 2008--turning science into medicine.
Dalziel C
IDrugs; 2008 Aug; 11(8):559-62. PubMed ID: 18683088
[No Abstract] [Full Text] [Related]
7. Emerging drugs for gastro-oesophageal reflux disease.
Wurm P; De Caestecker J
Expert Opin Emerg Drugs; 2005 May; 10(2):457-71. PubMed ID: 15934879
[TBL] [Abstract][Full Text] [Related]
8. 28th Annual JPMorgan Healthcare Conference--Exelixis and Nektar Therapeutics.
Gale S; Croasdell G
IDrugs; 2010 Mar; 13(3):139-41. PubMed ID: 20191424
[TBL] [Abstract][Full Text] [Related]
9. Digestive Disease Week 2010. Turning Science into Medicine--part 1.
Hodgkinson L
IDrugs; 2010 Jul; 13(7):421-3. PubMed ID: 20582860
[TBL] [Abstract][Full Text] [Related]
10. Cisapride and intestinal dysmotility: the final word?
Craig JS
Biol Neonate; 2005; 88(4):276-7. PubMed ID: 16113521
[No Abstract] [Full Text] [Related]
11. Digestive Disease Week 2010. Turning Science into Medicine--part 2.
Hodgkinson L
IDrugs; 2010 Jul; 13(7):424-6. PubMed ID: 20582861
[TBL] [Abstract][Full Text] [Related]
12. American society of clinical oncology--41st annual meeting.
Shah S; Yager N
IDrugs; 2005 Jul; 8(7):525-7. PubMed ID: 15973553
[No Abstract] [Full Text] [Related]
13. American Society of Clinical Oncology--41st annual meeting. Drug highlights I.
Shah S; Yager N
IDrugs; 2005 Jul; 8(7):531-3. PubMed ID: 15973555
[No Abstract] [Full Text] [Related]
14. Clinical trials of novel and targeted therapies: endpoints, trial design, and analysis.
Suman VJ; Dueck A; Sargent DJ
Cancer Invest; 2008 Jun; 26(5):439-44. PubMed ID: 18568764
[No Abstract] [Full Text] [Related]
15. Antimicrobial Agents and Resistance--Fifth International Symposium. Antifungal agents and novel vaccines.
Jacobs MR
IDrugs; 2005 Jul; 8(7):547-50. PubMed ID: 15973560
[No Abstract] [Full Text] [Related]
16. [Octreotide (Famsynthesis): new possibilities in gastroenterology].
Velichko MA; Vreshch VD
Voen Med Zh; 2001 May; 322(5):44-5. PubMed ID: 11550331
[No Abstract] [Full Text] [Related]
17. [Grounds and perspectives of using geviskon--novel in Russia alginate-containing drug--in treatment of acid-dependent diseases of the digestive system].
Tkachenko EI; Uspenskiĭ IuP
Eksp Klin Gastroenterol; 2007; (4):41-6. PubMed ID: 18409489
[No Abstract] [Full Text] [Related]
18. Epothilone D (Kosan/Roche).
Kolman A
Curr Opin Investig Drugs; 2004 Jun; 5(6):657-67. PubMed ID: 15242255
[TBL] [Abstract][Full Text] [Related]
19. Safety first: messages from Digestive Disease Week 2006.
Hanauer SB
Nat Clin Pract Gastroenterol Hepatol; 2006 Aug; 3(8):415. PubMed ID: 16883326
[No Abstract] [Full Text] [Related]
20. SOP 09: Statistical design and analysis.
Onkologie; 2003 Oct; 26 Suppl 6():43-7. PubMed ID: 23570186
[No Abstract] [Full Text] [Related]
[Next] [New Search]
